Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2013.

During the first quarter of 2013, Cadence reported net product revenue from sales of OFIRMEV® (acetaminophen) injection of $23.6 million, which includes the one-time recognition of $2.6 million in deferred revenue on previously shipped product. Consistent with other companies with products at this stage of commercialization, and based upon its determination it had obtained sufficient product return history to reasonably estimate future wholesaler returns, beginning on January 1, 2013, the company began to recognize revenue at the time that the product is sold to a wholesaler.

Excluding the recognition of $2.6 million in previously deferred revenue, net product revenue for the first quarter of 2013 was $21.0 million, which represents an increase of more than 160% from the $8.0 million in net product revenue recognized for the first quarter of 2012, and an increase of 23% from the $17.1 million recognized for the fourth quarter of 2012.

Highlights for the first quarter of 2013 included:

  • The gross margin on sales of OFIRMEV was 65% for the first quarter of 2013, as compared to 47% for the first quarter of 2012.
  • As of March 31, 2013, the company had over 4,000 unique customer accounts, an increase of nearly 50% from the first quarter of 2012.
  • The average order size by end-user customers increased 28% during the first quarter of 2013 as compared to the first quarter of 2012.
  • On March 12, 2013, the company announced that the Department of Veterans Affairs added OFIRMEV to the VA Natio
    '/>"/>

  • SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
    2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
    3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
    4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... Deerfield Management Company, L.P. today announced the ... will invest in groundbreaking advancements in science that may ... orphan diseases. The venture capital fund will also back ... and improve the way healthcare is delivered to patients. ... venture funds in the sector, will donate all profits ...
    (Date:7/28/2015)... , July 28, 2015 BioStructures, ... it has hit a milestone of 4,000 implantations ... FDA 510(k) cleared in early 2014 as a ... posterolateral spine fusion procedures.  This is a distinguished ... less than 6% of new synthetic products have ...
    (Date:7/28/2015)... ZIONA, Israel , ... Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing ... products, today announced that Shomrat Shurtz has been ... 20, 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... over 25 years of experience in marketing, regulatory ...
    (Date:7/27/2015)... /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or ... for the treatment of cancer, today provides the following ... closed a $1,000,000 unit offering private placement.  This financing ... the Company at a price of $0.06 per unit.  ... one common share purchase warrant.  Each whole warrant is ...
    Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Quest PharmaTech Closes $1,000,000 Private Placement 2
    ... 4, 2012  MedPlast, Inc., a technology and innovative ... Industrial specialty markets, announces the acquisition of United ... full-service manufacturer of precision plastic products and value-added ... with operations in the U.S., China, Mexico, and ...
    ... of chemotherapy and radiation has improved clinical outcomes, but ... The effectiveness of the treatment is limited by the ... chemotherapy access to the cancer cells and complicates surgical ... researchers from the Georgia Institute of Technology and Emory ...
    ... Researchers at the University of Montreal,s Sainte-Justine Hospital have ... able to build up resistance to opioid pain drugs within ... are often harvested from poppy plants, for centuries, but we ... in the hours, days and weeks following the first dose. ...
    Cached Biology Technology:MedPlast Acquires UPG 2MedPlast Acquires UPG 3Novel compound halts tumor spread, improves brain cancer treatment in animal studies 2Novel compound halts tumor spread, improves brain cancer treatment in animal studies 3Novel compound halts tumor spread, improves brain cancer treatment in animal studies 4Researchers reveal why some pain drugs become less effective over time 2
    (Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
    (Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
    (Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
    Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
    ... of mankind,s deadliest scourges, tuberculosis, is helping researchers at ... (NIST) and the Department of Energy,s Brookhaven National Laboratory ... what controls the switching on and off of genes ... a Journal of Biological Chemistry paper* posted ...
    ... new legal challenges, ,intelligent design in the courts, and ... was finally vindicated, ,creationism was booted out of the ... issued a clarion call to "restore science to its ... every day in school ,districts across the U.S. by ...
    ... 2009 Gov. Rick Perry today announced the awarding of ... the Texas Emerging Technology Fund (ETF). As a ... hormones researcher and his team to carry out laboratory research ... world-class center to be established by UH and The Methodist ...
    Cached Biology News:Long-sought protein structure may help reveal how 'gene switch' works 2Long-sought protein structure may help reveal how 'gene switch' works 3US science education organization updates analysis 2Internationally acclaimed researcher joins UH faculty thanks to $5.5 million grant 2Internationally acclaimed researcher joins UH faculty thanks to $5.5 million grant 3Internationally acclaimed researcher joins UH faculty thanks to $5.5 million grant 4Internationally acclaimed researcher joins UH faculty thanks to $5.5 million grant 5
    Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
    Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    PPIF Antibody...
    Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
    Biology Products: